


In the Claims

The listing of claims will replace all prior versions, and listings, of claims in the application.

What is claimed is:

1.-56. (Canceled)

57. (Currently amended) A method for treatment of ~~conditions or diseases associated with dysfunction of vascular endothelium, oxidative stress and/or insufficient production of endothelial PGI₂, hypertriglyceridemia in a subject in need thereof, said method comprising administering administration to [[a]] said subject in a need thereof a therapeutically effective amount of a pharmaceutically acceptable salt of 1-methylnicotinamide, a quaternary pyridinium salt of formula I:~~



I

wherein R is NH₂, CH₃ or N(H)CH₂OH, and X is a pharmaceutically acceptable counterion,

wherein said administering lowers said subject's plasma triglyceride level.

58. (Currently amended) The method in accordance with claim 57, wherein
~~said dysfunction of vascular endothelium, oxidative stress, and/or insufficient production~~
~~of endothelial prostacyclin PGI₂ coincides with hypercholesterolemia,~~
~~hypertriglyceridemia or low HDL levels~~ said administering raises said subject's plasma
HDL level.

59.-69. (Canceled)

70. (Currently amended) The method in accordance with claim 57, wherein
~~the pyridinium salt of formula I~~ said salt of 1-methylnicotinamide is administered orally.

71. (Currently amended) The method in accordance with claim 57, wherein
~~the pyridinium salt of formula I~~ said salt of 1-methylnicotinamide is administered
parenterally.

72.-78. (Canceled)

79. (Currently amended) The method in accordance with claim 57, wherein
~~said quaternary pyridinium salt of 1-methylnicotinamide~~ is in the form of a composition
with a pharmaceutically acceptable carrier.

80.-86. (Canceled)

87. (Currently amended) The method of claim 86 57, wherein said
hypertriglyceridemia is associated with a low plasma level of HDL.

88.-89. (Canceled)

90. (New) A method for treatment of dyslipidemia in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a pharmaceutically acceptable salt of 1-methylnicotinamide, wherein said administering raises said subject's HDL level and lowers said subject's plasma triglyceride level.

91. (New) The method of claim 90, wherein said salt of 1-methylnicotinamide is administered orally.

92. (New) The method of claim 90, wherein said salt of 1-methylnicotinamide is administered parenterally.

93. (New) The method of claim 90, wherein said salt of 1-methylnicotinamide is in the form of a composition with a pharmaceutically acceptable carrier.